The companies that survive will look less like pyramids and more like swarms: small, autonomous AI-first pods that move and ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Albany International Corp. (NYSE: AIN) announced today that it is exploring strategic alternatives for its structures assembly business, including a potential sale ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...
Systemic, structural change has always been a part of the perspective of the Greater Good Science Center. In a 2022 essay, editor Jeremy Adam Smith defines structural forces in the context of our work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback